

## Steve Kopko

---

**From:** Steve Kopko  
**Sent:** Friday, December 18, 2020 12:08 PM  
**To:** COADataStandards  
**Cc:** Steve Kopko; Dana Booth; Diane Corey; Motamed, Massoud  
**Subject:** \*\* Request Input \*\* HAMD 17 CRF and multiple references  
**Attachments:** HAMD 17 Annotated CRF.pdf; HAMD 1960 reference.pdf; HAMD\_1967 Reference Paper.pdf; 2005 AssessmentScales in Depression, Mania and Anxiety -Lam, Michalak, Swinson.pdf; HAMD with ref info from Guy ecdeu assessment manual.pdf; HAMD 17 Gold Standard Reference Paper.pdf; HAM-D ePROIDE Summary.pdf; QRS EMAIL DBooth HAMD 17 MRT Reference 2020-12-14.pdf

Helena,

We would appreciate your input on the FDA submission experience in reviewing the HAMD 17 instrument based on the differences we have found in the public domain versions of the HAMD 17 CRF (attached is the CRF obtained from an internet search that we have been using since the CDISC HAMD 17 version 1 supplement was released in 2012) and available reference papers. We were about to send the supplement for your internal review when these issues were identified. Attached are the following reference papers we have obtained:

1. Original 1960 HAMD 17 reference paper
2. Updated 1967 HAMD 17 reference paper
3. *Assessment Scales in Depression, Mania and Anxiety, Raymond W Lam, MD, FRCPC, Erin E. Michalak, PhD, Richard P Swinson, MD, FRCPsych, FRCPC, Copyright 2005 Taylor & Francis, an imprint of the Taylor & Francis Group.*
  - a. The HAMD 17 CRF described in this reference matches the CRF we have been using. This reference is copyrighted, so we cannot extract the CRF directly from the paper.
  - b. We think this CRF is more current than the CRF description in the 1960 and the 1967 reference paper.
4. The HAMD 17 instrument is also described in the “Guy W, *ECDEU Assessment Manual for Psychopharmacology*. Rockville, MD: US Department of Health, Education, and Welfare, 1976”.
  - a. This description more closely matches the CRF we are using, but does contain some differences. These differences are minor and do not change the interpretation of the items or responses. This CRF has differences in the following items:
    - i. Many of the response texts are different for several items
      1. Items 3 response of 3
      2. Item 7 response of 3
      3. Item 12 response of 2
      4. Etc.
    - ii. Item 4, 5, 6 names differ and item 6 response of 2
    - iii. Items 16 and 17 are in reverse order
    - iv. Item 16 A & 16B names
    - v. Includes items 18, 19, 20, 21 that are described, but not included in the total score
5. “The Hamilton Rating Scale for Depression: The making of a “gold standard” and the unmaking of a chronic illness, 1960–1980”
  - a. Describes the evolution the HAMD scales and the non-standard use over time.
6. The HAMD 17 reference in the Mapi Research Trust (MRT) instrument database that many sponsors utilize in obtaining instruments: <https://eprovide.mapi-trust.org/>.
  - a. This indicates the HAMD 17 was copyrighted by Wiley in 1967, which confuses CDISC, since other reference indicate the instrument is in the public domain.
  - b. Attached is Dana’s research in purchasing a minimal HAMD 17 reference paper from Wiley.

- c. CDISC has a partnership with MRT to assist in obtaining copyright permission for instruments that are requested for CDISC standards. We will query MRT on this reference based on our research.

Based on the reference papers 4. And 5., we can make a case for using the current CRF for the HAMD 17 CDISC standard, but would appreciate your thoughts on this before moving forward. We would appreciate your input regarding the FDA experience in reviewing the HAMD 17 instrument in historic submissions. These are the questions we would appreciate input in confirming the use of the current CRF:

1. Has the CRF we are implementing been used in your reviews or might there be another consistent HAMD 17 CRF version? In our research, there have seen different CRFs identified with different sorting of the items and different responses.
2. Do you support our research of the HAMD 17 and CRF we are using before we send the supplement for FDA review?

We want to resolve this issue to avoid it coming up with comments during the review. Please let us know if you would like to meet on this topic once you have researched it.

Thanks for your assistance on this topic.

Steve, Dana, & Diane

---

**From:** Dana Booth <[dbooth@cdisc.org](mailto:dbooth@cdisc.org)>

**Sent:** Monday, December 14, 2020 12:42 PM

**To:** Amy Palmer <[apalmer@cdisc.org](mailto:apalmer@cdisc.org)>

**Cc:** Steve Kopko <[skopko.external@cdisc.org](mailto:skopko.external@cdisc.org)>; Diane Corey <[dcorey@c-path.org](mailto:dcorey@c-path.org)>

**Subject:** Can we move forward? HAMD 17




Hi Amy,

I believe we can still move forward with our public domain version of the HAMD 17, but I would like to get your input.

We found out the other day that Wiley has a copyrighted HAM-D, but I believe that it is a copyright for their version, not all versions. (Just like British Association of Dermatology has a copyrighted version of the PASI, but there is still the public domain version out there. They're not the only ones to take a public domain instrument, modify as they want and slap their copyright on it.) Here's what I've done to check the Wiley version out. I purchased on-line access to what I thought was the CRF, but the Wiley access that I purchased gave me on-line access to a 1-page article, not the instrument:



Mail - Dana Booth -




https://c




Visit Publisher's site



**INFO**



**OUTLINE**



The good news is that I see two things of use:

1. It notes that each item is rated 0-4 or 0-2 and the 0-2 items are rated as either probably or definitely present.
2. "Hamilton provided brief descriptors of the anchor points, but no probe questions, in the expectation that the information would be gathered during the normal course of an unstructured clinical interview."

To the first point, our HAMD 17 does not score the 0-2 items with probably or definitely present. To the second point, it does confirm what we've seen, that there are many versions out there, and it shows no indication that Wiley now has exclusive copyright to all HAMDs. I think they've just made their own which is copyrighted and that we're still ok to go forward with what we have. Steve and I also both checked the US Copyright Office registration of copyrights after 1978 and there isn't one for the HAMD; anything prior to that would have to have the copyright symbol on it.

I think we should document the concern when we found out there was a Wiley copyright for a HAMD and document that we have used due diligence and don't believe our version is infringing upon their version. As long as we document this, we should be ok.

Can we move forward? We've had terminology out there for years; we're just trying to get the supplement done and to the FDA to look at.

Thanks,

**Dana Booth | Project Manager, Foundational Standards | QRS Co-lead**



**Clear Data. Clear Impact.**

Office +1.512.363.5826 | Mobile +1.503.551.5362  
401 West 15th Street, Suite 800 | Austin, TX 78701

[cdisc.org](http://cdisc.org)